October 04, 2017
Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir
– Agreements with the
Gilead has also expanded its licensing agreements with
Under these voluntary licensing agreements, the manufacturers may
produce BIC as a single agent or in fixed-dose combinations with other
HIV medicines. BIC is the fifth HIV agent to be licensed in Gilead’s
agreements with the MPP and generic manufacturers. Gilead and the MPP
recently expanded the geographic scope of the licensing agreements for
Gilead’s other HIV therapies to include
“These agreements allow for our licensees to provide generic versions of
our latest therapies to people living with HIV in the developing world,”
Voluntary licensing agreements are a key component of Gilead's efforts
to increase access to the company's therapies in the developing world.
Competition among manufacturers has reduced the lowest price of a Gilead
HIV generic therapy by 80 percent since 2006, to as low as
Gilead has filed a New Drug Application to the
BIC in combination with FTC/TAF as a single tablet regimen is an investigational treatment that has not been determined to be safe or efficacious and is not approved anywhere globally.
Gilead’s licensing agreements are available at www.gilead.com/responsibility, and the full MPP licensing agreement is available at www.medicinespatentpool.org.
About Gilead Sciences
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 10 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the
possibility that regulatory authorities may not approve BIC/FTC/TAF in
the currently anticipated timelines, and marketing approvals, if
granted, may have significant limitations on their use. As a result,
BIC/FTC/TAF may never be successfully commercialized. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended
For more information on
View source version on businesswire.com: http://www.businesswire.com/news/home/20171004005434/en/
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Michele Rest, 650-577-6935